Sensei Biotherapeutics Inc (SNSE) Stock Price, Quote & News

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

LabPsycho Nov. 14 at 9:51 PM

$SNSE Using LabPsycho's Artificial Artificial Intelligence to predict the future over 6 months in advance. Lets see any multibillion $$$ hedge fund come close to this post (and many others I have shared here).

0 · Reply

d_risk Nov. 14 at 12:57 PM

$SNSE - Sensei Biotherapeutics, Inc. - 10Q - Updated Risk Factors SNSE’s latest 10-Q risk factors spotlight urgent funding needs, uncertainty around strategic alternatives and restructuring, major dilution risk, expanded clinical and regulatory hurdles, heavy reliance on third parties and suppliers, heightened IP and litigation threats, intense competition, macroeconomic headwinds, and substantial doubt about going concern amid deep losses and workforce cuts. #Biotechnology #MacroeconomicChallenges #IntellectualProperty #ClinicalTrials #FundingRisk 🟢 Added 🟠 Removed https://d-risk.ai/SNSE/10-Q/2025-11-14

0 · Reply

BillionerOfKing Nov. 11 at 3:55 PM

$SNSE Current Stock Price: $9.44 No options data available.

0 · Reply

GeoffGains Nov. 7 at 9:55 PM

$SNSE | $GCTK | $ALPS | $BBGI Yes we do. Keep in mind it's only 700k float so I'm thinking it can get new 52wk high at 13$ on a beat.

0 · Reply

Tryitin Oct. 31 at 1:26 AM

$SNSE Daily candle closed above the previous one indicating bullish sentiment even inspite of news this morning. I think this will either have asset sale news or some pump soon before it goes to oblivion !

0 · Reply

OnlyFibs Oct. 30 at 11:47 PM

RECAP 10/30 +Pos Comments: $MC + Seaport $ASX + Nomura $AAP + CFRA RECAP 10/30 -Neg Comments: $SNSE - HC Wainwright $FFWM - DA Davidson

0 · Reply

topstockalerts Oct. 30 at 10:44 PM

After Hours Top Gainers PT2 $AMZU $RDTL $ATEC $SNSE $METC $ETHA

0 · Reply

ChaseDeluca Oct. 30 at 10:29 PM

QCLS is literally built for explosive upside. $20+++ next week????? Quantum infrastructure + blockchain tech in a nano-float wrapper… New ticker. New story. And a chart that’s tightening by the hour. When this breaks it could go vertical. $PRST $GENE $ASST $SNSE $BYND !!!!

0 · Reply

Tryitin Oct. 30 at 10:10 PM

$SNSE RSI at 16 could enter here to make some profit for swing

0 · Reply

LithiumMakesMeHard Oct. 30 at 9:37 PM

$HBIO $INTS $IXHL $NCEL $SNSE $HBIO that was your last chance to dip buy before 90s and possible $1

0 · Reply

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 9:00 AM EDT - 15 days ago

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Oct 17, 2025, 8:00 AM EDT - 4 weeks ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sep 23, 2025, 7:30 AM EDT - 7 weeks ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 3, 2025, 8:00 AM EDT - 2 months ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 7:30 AM EDT - 3 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 7:30 AM EDT - 3 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jun 13, 2025, 7:30 AM EDT - 5 months ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 6 months ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 8 months ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 8 months ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 8 months ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 10 months ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 11 months ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 1 year ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 1 year ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 1 year ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Jun 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 18, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

Mar 28, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Mar 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Mar 14, 2023, 4:35 PM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

LabPsycho Nov. 14 at 9:51 PM

0 · Reply

d_risk Nov. 14 at 12:57 PM

0 · Reply

BillionerOfKing Nov. 11 at 3:55 PM

$SNSE Current Stock Price: $9.44 No options data available.

0 · Reply

GeoffGains Nov. 7 at 9:55 PM

$SNSE | $GCTK | $ALPS | $BBGI Yes we do. Keep in mind it's only 700k float so I'm thinking it can get new 52wk high at 13$ on a beat.

0 · Reply

Tryitin Oct. 31 at 1:26 AM

0 · Reply

OnlyFibs Oct. 30 at 11:47 PM

RECAP 10/30 +Pos Comments: $MC + Seaport $ASX + Nomura $AAP + CFRA RECAP 10/30 -Neg Comments: $SNSE - HC Wainwright $FFWM - DA Davidson

0 · Reply

topstockalerts Oct. 30 at 10:44 PM

After Hours Top Gainers PT2 $AMZU $RDTL $ATEC $SNSE $METC $ETHA

0 · Reply

ChaseDeluca Oct. 30 at 10:29 PM

0 · Reply

Tryitin Oct. 30 at 10:10 PM

$SNSE RSI at 16 could enter here to make some profit for swing

0 · Reply

LithiumMakesMeHard Oct. 30 at 9:37 PM

$HBIO $INTS $IXHL $NCEL $SNSE $HBIO that was your last chance to dip buy before 90s and possible $1

0 · Reply

LithiumMakesMeHard Oct. 30 at 9:32 PM

$HBIO $INTS $IXHL $NCEL $SNSE HBIO runnnning. Little cool off before we head to the 90s and eventually a dollar. Here’s your dip to buy

0 · Reply

FaReSx99 Oct. 30 at 9:11 PM

$SNSE 💥💥💥

0 · Reply

LithiumMakesMeHard Oct. 30 at 9:10 PM

$ADVB $HBIO $INTS $NCEL Can’t forget $SNSE !

0 · Reply

LithiumMakesMeHard Oct. 30 at 9:02 PM

$HBIO $INTS $IXHL $NCEL $SNSE HBIO next to run, heating up

0 · Reply

OpenOutcrier Oct. 30 at 8:00 PM

RECAP 10/30 +Pos Comments: $MC + Seaport $ASX + Nomura $AAP + CFRA RECAP 10/30 -Neg Comments: $SNSE - HC Wainwright $FFWM - DA Davidson Live Breaking trading news www.openoutcrier.com

0 · Reply

80sActionHero Oct. 30 at 4:32 PM

$SNSE This is the best shorting opportunity I've ever seen. They have no remaining clinical assets worth more than and they're bleeding cash. They've shut down their ONLY clinical trial and they've openly stated they're winding down operations. All they have are a few molecules that are in pre-clinical and those typically don't go for much. Maybe $5 million or something and likely less as they're now under a time and financial crunch and bidders know they can just buy the assets at fire sale prices in a bankruptcy auction if they even want them to begin with. Honestly, it's bizarre anyone is buying this stock at all with the news released today. There's no chance of a merger as they have nothing to offer of value. They're not initiating a new clinical trial on any of their pre-clinicals. That also tells you that they don't think they're worth much. They could have done secondary offerings and wasted investor money but they chose to be honest. I respect them. But it's a gift of a short.

1 · Reply

psychohaiko Oct. 30 at 3:58 PM

$SNSE thx Löwenjens für die satten gains

0 · Reply

Tradeforlosses Oct. 30 at 2:13 PM

$SNSE @GoodGoyim You catch this bro? Should make for a good short.

1 · Reply

Tradeforlosses Oct. 30 at 2:06 PM

$SNSE In for the long dump to under 1 dollar what a failure of a company

0 · Reply

notreload_ai Oct. 30 at 2:01 PM

$SNSE discontinues solnerstotug development and begins strategic review including potential sale, merger, or wind-down to maximize shareholder value. https://notreload.xyz/sensei-biotherapeutics-halts-drug-development-explores-strategic-options/

0 · Reply

StocktwitsNews Oct. 30 at 1:41 PM

Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options $SNSE $VXF https://stocktwits.com/news/equity/markets/sensei-biotherapeutics-halts-lead-drug-development-explores-sale-or-merger-options/cLGFvQbR3xf

0 · Reply

DaBullRunner Oct. 23 at 3:42 PM

$ARMP $SNSE MARK MY WORDS One of these two could pull a $SPRB type move🚨 $SCNX $BYND like I said know these things👇

3 · Reply

Market Cap	11.38M
Revenue (ttm)	0.00
Net Income (ttm)	-30.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	22,900
Avg Vol	37,986
Day's Range	N/A - N/A
Shares Out	1.26M
Stochastic %K	15%
Beta	0.31
Analysts	Hold
Price Target	$35.00